Literature DB >> 26039212

Haploidentical HSCT: a 15-year experience at San Raffaele.

C Bonini1, J Peccatori2, M T L Stanghellini2, L Vago2, A Bondanza1, N Cieri1, R Greco2, M Bernardi2, C Corti2, G Oliveira1, E Zappone2, C Traversari3, C Bordignon4, F Ciceri2.   

Abstract

Hematopoietic SCT (HSCT) from HLA haploidentical family donors is a promising therapy for high-risk hematological malignancies. In the past 15 years at San Raffaele Scientific Institute, we investigated several transplant platforms and post transplant cellular-based interventions. We showed that T cell-depleted haploidentical transplantation followed by the infusion of genetically modified donor T cells (TK007 study, Eudract-2005-003587-34) promotes fast and wide immune reconstitution and GvHD control. This approach is currently tested in a phase III multicenter randomized trial (TK008 study, NCT00914628). We targeted patients with advanced leukemia with a sirolimus-based, calcineurin inhibitor-free prophylaxis of GvHD to allow the safe infusion of unmanipulated PBSCs from haploidentical family donors (TrRaMM study, Eudract 2007-5477-54). Results of these approaches are summarized and discussed.

Entities:  

Mesh：

Year:  2015        PMID： 26039212     DOI： 10.1038/bmt.2015.99

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


  49 in total

1.  Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells.

Authors:  Alessandra Recchia; Chiara Bonini; Zulma Magnani; Fabrizia Urbinati; Daniela Sartori; Sara Muraro; Enrico Tagliafico; Attilio Bondanza; Maria Teresa Lupo Stanghellini; Massimo Bernardi; Alessandra Pescarollo; Fabio Ciceri; Claudio Bordignon; Fulvio Mavilio
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

2.  Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft.

Authors:  P Tiberghien; C Ferrand; B Lioure; N Milpied; R Angonin; E Deconinck; J M Certoux; E Robinet; P Saas; B Petracca; C Juttner; C W Reynolds; D L Longo; P Hervé; J Y Cahn
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

3.  Improved outcome with T-cell-depleted bone marrow transplantation for acute leukemia.

Authors:  F Aversa; A Terenzi; A Carotti; R Felicini; R Jacucci; T Zei; P Latini; C Aristei; A Santucci; M P Martelli; I Cunningham; Y Reisner; M F Martelli
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

4.  Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation.

Authors:  Fabio Ciceri; Chiara Bonini; Sarah Marktel; Elisabetta Zappone; Paolo Servida; Massimo Bernardi; Alessandra Pescarollo; Attilio Bondanza; Jacopo Peccatori; Silvano Rossini; Zulma Magnani; Monica Salomoni; Claudia Benati; Maurilio Ponzoni; Luciano Callegaro; Paolo Corradini; Marco Bregni; Catia Traversari; Claudio Bordignon
Journal:  Blood       Date:  2007-02-27       Impact factor: 22.113

5.  Herpes simplex thymidine kinase gene-transduced donor lymphocyte infusions.

Authors:  Richard K Burt; William R Drobyski; Tatiana Seregina; Ann Traynor; Yu Oyama; Carolyn Keever-Taylor; Jacob Stefka; Timothy M Kuzel; Mary Brush; Julianne Rodriquez; Willam Burns; Lucinda Tennant; Charles Link
Journal:  Exp Hematol       Date:  2003-10       Impact factor: 3.084

6.  Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery.

Authors:  Anna Dodero; Cristiana Carniti; Anna Raganato; Antonio Vendramin; Lucia Farina; Francesco Spina; Carmelo Carlo-Stella; Simona Di Terlizzi; Marco Milanesi; Paolo Longoni; Lorenza Gandola; Claudia Lombardo; Paolo Corradini
Journal:  Blood       Date:  2009-02-11       Impact factor: 22.113

7.  CD8+ cell depletion of donor lymphocyte infusions using cd8 monoclonal antibody-coated high-density microparticles (CD8-HDM) after allogeneic hematopoietic stem cell transplantation: a pilot study.

Authors:  E P Alyea; C Canning; D Neuberg; H Daley; H Houde; S Giralt; R Champlin; K Atkinson; R J Soiffer
Journal:  Bone Marrow Transplant       Date:  2004-07       Impact factor: 5.483

8.  Gene and cell therapy for relapsed leukemia after allo-stem cell transplantation.

Authors:  Masafumi Onodera
Journal:  Front Biosci       Date:  2008-05-01

9.  Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.

Authors:  Xiao-Jun Huang; Dai-Hong Liu; Kai-Yan Liu; Lan-Ping Xu; Huan Chen; Wei Han; Yu-Hong Chen; Xiao-Hui Zhang; Dao-Pei Lu
Journal:  Biol Blood Marrow Transplant       Date:  2009-02       Impact factor: 5.742

10.  The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo.

Authors:  E Todisco; F Ciceri; E Oldani; C Boschini; C Micò; M T Vanlint; I Donnini; F Patriarca; P E Alessandrino; F Bonifazi; W Arcese; W Barberi; P Marenco; E Terruzzi; S Cortelazzo; S Santarone; A Proia; P Corradini; E Tagliaferri; S Falcioni; G Irrera; L Dallanegra; L Castagna; A Santoro; A Camboni; N Sacchi; A Bosi; A Bacigalupo; A Rambaldi
Journal:  Leukemia       Date:  2013-07-09       Impact factor: 11.528
View more
  3 in total

Review 1.  Retroviral vectors and transposons for stable gene therapy: advances, current challenges and perspectives.

Authors:  José Eduardo Vargas; Leonardo Chicaybam; Renato Tetelbom Stein; Amilcar Tanuri; Andrés Delgado-Cañedo; Martin H Bonamino
Journal:  J Transl Med       Date:  2016-10-12       Impact factor: 5.531

Review 2.  Development and Clinical Translation of Approved Gene Therapy Products for Genetic Disorders.

Authors:  Alireza Shahryari; Marie Saghaeian Jazi; Saeed Mohammadi; Hadi Razavi Nikoo; Zahra Nazari; Elaheh Sadat Hosseini; Ingo Burtscher; Seyed Javad Mowla; Heiko Lickert
Journal:  Front Genet       Date:  2019-09-25       Impact factor: 4.599

Review 3.  Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel.

Authors:  Francesca Bonifazi; Marie-Thérèse Rubio; Andrea Bacigalupo; Jaap Jan Boelens; Jürgen Finke; Hildegard Greinix; Mohamad Mohty; Arnon Nagler; Jakob Passweg; Alessandro Rambaldi; Gérard Socie; Carlos Solano; Irwin Walker; Giovanni Barosi; Nicolaus Kröger
Journal:  Bone Marrow Transplant       Date:  2020-01-22       Impact factor: 5.483
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.